OECD ADVERSE OUTCOME PATHWAY

Project Submission Form

If you require further information please contact the OECD Secretariat Delrue (Nathalie.delrue@oecd.org)

Return completed forms to our generic account (env.tgcontact@oecd.org), and Nathalie

PROJECT TITLE

Dopamine agonism/ enhancement leading to Leydig cell tumor

SUBMITTED BY (Country / European Commission / Secretariat)

Japan

DATE OF SUBMISSION TO THE SECRETARIAT

Nov. 14th, 2018

DETAILS OF LEAD COUNTRY/CONSORTIUM

<table>
<thead>
<tr>
<th>Country/Organisation:</th>
<th>Japan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agency/ministry/Other:</td>
<td>Japan Pharmaceutical Manufacturers Association</td>
</tr>
<tr>
<td>Contact person(s):</td>
<td>Kenjiro Tsubota</td>
</tr>
<tr>
<td>Mail Address:</td>
<td>5-36-1, Shimosakunobe, Takatsu-ku, Kawasaki-city, Kanagawa, 213-8522, Japan</td>
</tr>
<tr>
<td>Phone/fax:</td>
<td>+8144-812-8634</td>
</tr>
<tr>
<td>Email:</td>
<td><a href="mailto:kenjiro.tsubota@astellas.com">kenjiro.tsubota@astellas.com</a></td>
</tr>
</tbody>
</table>

PROJECT CATEGORY

☒ Development of an AOP - applicable to a chemical category

☐ AOP-Wiki ☐ Effectopedia

☐ Guidance document related to AOP development including its evaluation

☐ Knowledge management tool for supporting AOP development including its evaluation
During the decades of drug development with rodent carcinogenicity studies, some classes of pharmaceuticals are known to induce tumors with non-genotoxic mechanisms based on their on-target or off-target pharmacology as well as toxicity; some are mostly common in rodents and the others might be extrapolated to humans. One of these non-genotoxic carcinogenesis is Dopamine agonism/ enhancement-induced Leydig cell tumor and we propose to develop the AOP.

In the rat, dopamine agonists decrease prolactin (PRL) secretion in the pituitary. Decreased serum PRL downregulates LH receptor on Leydig cells and subsequently decreases testosterone production. To compensate decreased testosterone level, LH secretion increases and eventually results in Leydig cell hyperplasia and Leydig cell tumor.

The risk of dopamine agonism/ enhancement-induced Leydig cell tumor development in human deems to be low compared with rodents considering the following difference between rats and humans. Cook et al. suggested that the Leydig cell tumor is common spontaneous tumor and often induced in response to some chemicals, whereas quite rare tumor in humans (0.00004%). Leydig cell in rats has more receptors for GnRH, PRL and LH and is more sensitive to increased levels of gonadotropin than that in humans [1].

Note: For AOP Development projects please indicate the extent of the pathway to be described (i.e. the anchor points), the intermediate events that are likely to be addressed, the state of current development, the degree to which this pathway is already understood and described in the literature, and the expectation on the availability of evidence to support the AOP. Proposers should also indicate if and how the AOP is associated to any regulatory toxicological endpoints (e.g. acute or chronic toxicity, toxicity to reproduction etc.) Please provide references, links or attachments for supplementary information.

PROJECT PLANNING

In this section, please provide an indication of when the project is likely to commence and the expected duration. Please also make reference to any particular milestones or external
factors that will influence project planning, and if the project is linked to programmes of particular organisations or consortia.

The Japanese Pharmaceutical Manufacturers Association (JPMA) will develop several AOPs for non-genotoxic carcinogenesis based on our survey on the pharmacology-induced modes of action of carcinogenesis in the next four years under the cooperation of Dr. Kumiko Ogawa (National Institute of Health Sciences).

The timeline of the development of the present AOP is as follows:

- Nov., 2018: to submit the AOP SPSF
- Jun., 2019: to complete AOP Wiki input and wiki input and request an internal review by EAGMST

FLOW DIAGRAM

In this section, please provide a flow diagram of the proposed AOP, including the MIE, KEs at the various stages (molecular interaction, cellular response, organ response) and the AO.

<table>
<thead>
<tr>
<th>Level of Organization</th>
<th>AOP Diagram</th>
</tr>
</thead>
<tbody>
<tr>
<td>Macro-molecular</td>
<td>Dopamine agonism</td>
</tr>
<tr>
<td>Cell/Tissue</td>
<td>Decrease in prolactin secretion</td>
</tr>
<tr>
<td>Organ/Organ System</td>
<td></td>
</tr>
<tr>
<td>Individual</td>
<td></td>
</tr>
</tbody>
</table>

References